drugset / Trial / NCT05075083
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD
Phase 4
Unknown
400 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collabZhejiang Provincial Center for Disease Control and Prevention · collab
NaSingle-groupOpen-labelPrevention
Summary
Evaluation of immunogenicity and safety of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days .
Timeline
- Start
- 2021-10-08
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CoronaVac | Vaccine | — | — |